Allergan Aesthetics' Boey Just Won Health Canada Approval — A Rapid-Onset Neuromodulator Option

Boey is a rapid-onset, short-duration botulinum toxin product approved by Health Canada for treating glabellar lines. Unlike traditional neuromodulators, Boey works faster and wears off sooner, making it ideal for patients who want quicker results or prefer a lower-commitment option before committing to longer-lasting treatments.

Boey has a faster onset profile than traditional botulinum toxin products like Botox and Dysport, though specific onset timelines were not detailed in the approval announcement. The rapid-onset characteristic is a key differentiator designed to appeal to patients seeking quicker visible results.

Boey has only received Health Canada approval for the Canadian market at this time. The U.S. approval status remains unclear, though the Canadian approval may signal future regulatory activity with the FDA.

Short-duration products like Boey lower the barrier to entry for first-time neuromodulator patients who are hesitant about longer-lasting commitments, while rapid-onset formulations appeal to patients wanting quicker results. Both positioning strategies can expand your patient base and increase treatment frequency.

Boey is currently indicated for glabellar lines (the vertical lines between the eyebrows). The approval is limited to this indication based on Health Canada's authorization.